Financial Performance - Net income available to common shareholders (NIAC) for 2025 was $956 million, a 29% increase compared to $738 million in 2024[7] - Diluted EPS for 2025 was $187, a 38% increase compared to $136 in 2024[7] - Adjusted EPS for 2025 was $189, up 22% from 2024[11] - Adjusted pre-tax income increased by 14% from 2024 to $13 billion[13] - The company deployed over $12 billion of excess capital, including $894 million in stock buybacks and $307 million in dividends[13] Balance Sheet and Capital - Period-end loans reached $642 billion, a 3% increase compared to $626 billion at the end of 2024[7] - Period-end deposits reached $675 billion, a 3% increase compared to $656 billion at the end of 2024[7] - Tangible book value per share (TBVPS) increased by 11% to $1420 from $1285 in 2024[7] - CET1 ratio was 1064%[11] Asset Quality - Net charge-offs (NCO) were 019% of total loans[11]

Project Highlights - Three US-based organic growth projects are expected to add a cumulative Net Present Value (NPV) of $41 billion at a gold price of $4,300/oz[13] - The combined Internal Rate of Return (IRR) for these projects is projected to be 55% at a gold price of $4,300/oz[13] - The projects are expected to have a quick payback period[13] - The average incremental All-In Sustaining Cost (AISC) for these projects is estimated to be approximately $1,650/oz[13] - The projects are expected to contribute nearly 3 million ounces of gold equivalent production over their Life of Mine (LOM)[13] Round Mountain - Phase X - Phase X is projected to have an NPV of $1881 million and an IRR of 67% at a gold price of $4,300/oz[22] - The project is expected to produce 14 million ounces of gold equivalent over its LOM[22] - The average grade is expected to be 30 g/t[22] Curlew - Curlew is projected to have an NPV of $1171 million and an IRR of 44% at a gold price of $4,300/oz[61] - The project is expected to produce 09 million ounces of gold equivalent over its LOM[61] - The average grade is expected to be 58 g/t[61] Bald Mountain - Redbird 2 - Redbird 2 is projected to have an NPV of $969 million and an IRR of 58% at a gold price of $4,300/oz[99] - The project is expected to produce 064 million ounces of gold equivalent over its LOM[99] - The average grade is expected to be 05 g/t[99]

Financial Performance & Goals - Morgan Stanley achieved a Return on Tangible Common Equity (ROTCE) of 21.6%[9] - The firm's Earnings per Share (EPS) reached $10.21[9] - Total Client Assets amounted to $9.3 Trillion[9] - The firm is targeting $10 Trillion+ in Client Assets[19, 57] - The firm is targeting a ROTCE of 20%[19, 57] Wealth Management - Wealth Management's Pre-Tax Margin is targeted at 30%[19, 57] - Wealth Management's net revenues increased from $19 Billion in 2020 to $32 Billion in 2025[26] - Fee-Based Flows in Wealth Management were approximately $735 Billion from 2021-2025, compared to approximately $330 Billion from 2016-2020[26] - Net New Assets in Wealth Management were approximately $1.64 Trillion from 2021-2025, compared to approximately $580 Billion from 2016-2020[26] Institutional Securities & Investment Management - Institutional Securities Wallet Share increased from approximately 14.3% in 2020 to approximately 15.5% in 2025[16]

Acquisition Highlights - Talen is investing $3.45 billion in Lawrenceburg, Waterford, and Darby assets [6] - ECP is supporting the acquisition with approximately $900 million in Talen equity [6] - The acquisition is expected to be immediately >15% accretive to Adjusted Free Cash Flow (FCF) per share [6, 17, 19] - The acquisition diversifies Talen's generation portfolio with the addition of approximately 2.62 GW of efficient natural gas assets [6] Financial Metrics - The acquisition represents a 6.6x 2027E Adjusted EBITDA multiple with approximately 85% unlevered free cash flow conversion [6] - The purchase price consists of approximately $2.55 billion in cash and approximately $900 million in Talen equity, with 2.4 million shares to be issued to ECP (~5% of expected pro forma equity) [17] - The transaction is expected to generate more than $1 billion in nominal tax shield benefits [17] - Talen aims to achieve <3.5x net leverage target by year-end 2026 [6, 17] Portfolio Impact - The acquisition adds approximately 2.6 GW of PJM gas capacity in Ohio and Indiana [8] - The acquired assets are expected to generate approximately 15.7 TWh of electricity in 2024 [11] - Pro forma annual generation is expected to approximately double after recent acquisitions, reaching ~71 TWh [14]

Transaction Overview - Aspen is selling 100% of its equity interests and intellectual property assets in Australia, New Zealand, and other Asia Pacific regions (excluding China) [35] - The gross unadjusted consideration is AUD 2.37 billion (ZAR 26.477 billion) [16, 42] - The transaction represents an EV/Normalised EBITDA (FY 2025) multiple of approximately 11x [16, 42] - Transaction and other costs are expected to be less than 5% of the net proceeds [17] Financial Performance (FY 2025) - APAC revenue was R7.792 billion, representing 18% of the Group's total revenue of R43.3 billion [12] - APAC EBITDA was R2.445 billion, representing 26% of the Group's total EBITDA of R9.324 billion [14] Strategic Rationale - The divestment aligns with the Group's strategy to unlock the underlying sum-of-the-parts value [39] - The transaction will improve balance sheet flexibility for future capital allocation [20, 39] - The company will have a heightened focus on the Group's growth drivers, including Commercial Pharma and sterile FDF manufacturing [20, 39] Anticipated Timelines - Post circular to shareholders is expected on or before 20 March 2026 [24] - Shareholder vote is scheduled for on or before 22 April 2026 [24] - Transaction completion is expected by the end of May 2026 [24]

Transaction Overview - Boston Scientific announced a definitive agreement to acquire Penumbra, valuing the company at $374 per share[10] - The transaction consideration reflects a total equity value of $15 billion, funded by approximately $11 billion in cash and approximately $4 billion in Boston Scientific stock, resulting in a 73% cash, 27% stock mix[29] - The equity issuance is expected to be approximately 41 million shares, fixed at the time of signing based on Boston Scientific's 10-day VWAP ending January 13, 2026[29] - The transaction is expected to close in 2026, subject to Penumbra shareholder approval and customary closing conditions[28, 29] Penumbra Financials and Market Opportunity - Penumbra's Q4 2025 reported revenue growth is +21.4-22.0% compared to 2024[13] - Penumbra's FY25 reported revenue growth is +17.3-17.5% compared to 2024[13] - Penumbra's FY25E gross margin is 67.9-68.1% and operating margin is 13.3-13.6%[13] - Penumbra operates in large, underserved spaces including mechanical thrombectomy, embolization, and neurovascular segments[10] - The total annual U S opportunity includes 315,000+ peripheral patients and 175,000 MMAe patients[16] Strategic Rationale - The acquisition provides Boston Scientific with entry into new key segments with a WAMGR accretive to Boston Scientific[10] - The combination is expected to deliver meaningful revenue contribution and cost efficiencies, supporting long-range planning goals[10] - Penumbra has a WAMGR of approximately 11% in high-growth adjacent areas[18]

Financial Performance - BlackRock's Assets Under Management (AUM) reached $14.0 trillion as of December 31, 2025[2] - Q4 2025 Base Fees and Securities Lending Revenue totaled $5.3 billion[2] - Q4 2025 Operating Income, as adjusted, was $2.848 billion[8] - Q4 2025 EPS, as adjusted, reached $13.16[9] Asset Flows and Growth - Total BlackRock experienced net inflows of $82 billion in Q4 2025[5] - ETFs Long-term organic asset growth rate was 12% in Q4 2025[5] - Long-term Cash organic asset growth rate was 3% in Q4 2025[5] Revenue Analysis - Base fees accounted for 73% of quarterly revenue[22] - Base fees increased by 20% year-over-year and 5% sequentially in Q4 2025[22] - Performance fees increased by 67% year-over-year and 46% sequentially in Q4 2025[22] Expense Analysis - Employee compensation & benefits increased by 28% year-over-year and 9% sequentially in Q4 2025[34]

2026 CORPORATE PRESENTATION January 2026 PHARMACEUTICALS INC. Various statements in this presentation, including, but not limited to, the guidance provided under "2025 Financial Guidance" and statements regarding Vanda's commercial products, plans, priorities and opportunities, as well as statements about Vanda's strategic focus and its products in development and the related clinical development and regulatory timelines and commercial and therapeutic potential for such products, are "forward-looking statem ...

Disclaimer Accelerating Energy Transition Through Battery Materials Discovery and Health Management January 2026 Although all information and opinions expressed in this Presentation, including market data and other statistical information, were obtained from sources believed to be reliable and are included in good faith, SES has not independently verified the information and makes no representation or warranty, express or implied, as to its accuracy or completeness. Some data is also based on the good faith ...

Corporate Overview January 2026 © ALX Oncology Inc. All rights reserved. Forward-looking Statements Certain information set forth in this presentation contains "forward-looking information", under applicable laws collectively referred to herein as forward-looking statements. Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to the (i) results and cost and timing of our product development activities and clinical tri ...